US and European Regulators Find Serious Deficiencies in Six Indian Pharma Factories

Serious questions have once again been raised regarding the quality of the Indian pharmaceutical industry. Over the last three months, drug regulators from the US and Europe have discovered severe quality-related deficiencies in six Indian drug factories and one testing laboratory. The investigations specifically revealed poor infection control measures during the production of injections, negligence in machine cleaning, and serious discrepancies in testing records. According to a report by Amar Ujala, the Government of India is now preparing to take strict action following these incidents.

American drug regulators have sent warning letters to three companies and one testing laboratory. Yuzia Pharma, located in Telangana, was warned on August 13 as the measures to prevent infection while manufacturing injections were found to be extremely poor. On the other hand, larger irregularities were observed at the Reliance Life Sciences factory in Navi Mumbai. A letter issued on August 18 mentioned that results were recorded in the logs without proper testing of the samples.

The condition of the Shulin Pharma factory in the Mehsana district of Gujarat was also found to be concerning. During the inspection, filth, rust in machines, and traces of old chemicals were observed. Due to these serious deficiencies, the US has not only sent a warning letter to the company but has also placed an 'import alert' on medicines sent by this company to the US. Additionally, serious flaws were found in a testing lab named Origa Research. A warning letter sent to the lab on August 12 stated that the original records of the samples were incomplete. Furthermore, when testing results exceeded prescribed standards, tests were repeatedly conducted without any concrete reason to discard the initial results.

European drug regulators have also noted serious deficiencies in three Indian factories. Major flaws in cleanliness, the condition of machinery, and testing records were found at the Ananta Medicare factory in Sri Ganganagar, Rajasthan. Serious deficiencies regarding machine cleaning were found at the AcuLife Healthcare factory in the Ahmedabad district of Gujarat. The European report noted one critical, eight major, and 24 other deficiencies in this factory. At the Gluchem Biocare factory in Siddipet, Telangana, residues of water and filth were found inside the machines even after cleaning.

Following such serious lapses in drug quality, the Government of India is now set to take strict legal action. A proposal has been put forward by the Central Government to amend the 'Drugs Rules, 1945'. After the implementation of this amendment, if any deficiency in quality standards is found in the medicines of any drug manufacturing company, the government will be able to suspend the manufacturer's license with immediate effect. The primary objective of this step is to bring transparency to the Indian pharmaceutical industry and maintain quality at an international level, so that the credibility of Indian medicines is preserved in the global market.